8-K: Oramed Transfers POD Tech to Lifeward, Becomes Key Shareholder

Oramed Pharmaceuticals Inc. has announced a strategic transaction to transfer its oral drug delivery technology to Lifeward Ltd., becoming a significant shareholder and investor in the medical robotics company.

Summary

• Oramed Pharmaceuticals Inc. (Oramed) is transferring its proprietary Protein Oral Drug (POD) delivery technology to Lifeward Ltd. (Lifeward).
• In exchange, Oramed will receive a beneficial ownership interest in Lifeward of up to 49.99% of Lifeward's fully diluted equity capitalization, initially capped at 45.0% of outstanding Lifeward Ordinary Shares at closing, including shares and warrants.
• Oramed will also receive revenue-based payments equal to 4% of Net Revenue from Lifeward's ReWalk Personal Exoskeleton products and related extended warranties.
• These revenue sharing payments will continue for up to 10 years, or until Oramed receives an aggregate of up to $40 million (including a base of $20 million plus two times any debt or equity investment by Oramed in Lifeward post-closing), or until Lifeward's market capitalization reaches $200 million.
• Oramed is investing $9 million in an initial $10 million private placement of Lifeward's senior secured convertible notes, which bear an 8% annual interest rate and come with 100% warrant coverage.
• An additional $10 million in senior secured convertible notes, with Oramed investing another $9 million, is contingent upon Lifeward achieving specific commercial milestones (150% increase in ReWalk Unit Sales or a share price of $1.15 for 10 consecutive trading days).
• Oramed will manage the clinical study of Oratech Pharma, Inc.'s investigational oral insulin capsule product under a clinical trial management agreement, with reimbursement for expenses up to a specified aggregate amount.
• Oramed has entered into a lock-up agreement, restricting the transfer of its Lifeward shares for 120 days post-closing.
• The transaction is subject to customary closing conditions, including Lifeward shareholder approval for the issuance of more than 19.99% of its outstanding ordinary shares.

Sentiment

Score: 7

Explanation: The transaction is strategically positive for both companies, providing Oramed with diversified exposure and Lifeward with new technology and significant funding. However, the execution is subject to shareholder approvals and performance milestones, introducing some uncertainty.

Positives

• Oramed shareholders retain significant exposure to the oral drug delivery platform through a substantial ownership stake in Lifeward.
• Oramed gains meaningful participation in a revenue-generating medical robotics business, diversifying its strategic assets.
• Lifeward acquires Oramed's POD technology, opening new growth opportunities in oral drug delivery.
• The strategic investment by Oramed provides Lifeward with financial resources to pursue profitability for its ReWalk and AlterG product lines.
• Lifeward's CEO, Mark Grant, brings over 25 years of healthcare and medical technology experience, including significant leadership in the diabetes sector, which is beneficial for advancing the oral insulin program.

Negatives

• The transaction's completion is contingent on Lifeward's shareholder approval, which introduces uncertainty.
• The additional $10 million investment by Oramed is milestone-based, meaning it is not guaranteed and depends on Lifeward's future commercial performance or share price.
• Oramed's shares in Lifeward are subject to a 120-day lock-up period, limiting immediate liquidity.
• The revenue sharing payments are capped at a maximum amount of $40 million, limiting long-term upside from the ReWalk franchise beyond that threshold.

Risks

• Failure to obtain Lifeward shareholder approval for the issuance of shares exceeding 19.99% of its outstanding ordinary shares could prevent the transaction from closing.
• Lifeward may not achieve the commercial milestones (150% increase in ReWalk Unit Sales or $1.15 share price for 10 consecutive trading days) required to trigger the additional $10 million convertible note investment.
• Regulatory review by the SEC for the resale registration statement could be prolonged, potentially delaying the liquidity of Oramed's Lifeward shares.
• The market capitalization of Lifeward may not reach $200 million, which is a condition for the termination of revenue sharing payments, potentially extending the payment period or limiting the total amount received.
• The value of the warrants and convertible notes is subject to market fluctuations of Lifeward's ordinary shares.

Future Outlook

Lifeward aims to achieve profitability with its existing ReWalk and AlterG product lines while simultaneously pursuing significant growth opportunities through the newly acquired POD technology. Oramed anticipates managing the upcoming clinical trial for the oral insulin program. The transaction is expected to provide Lifeward with financial resources to advance both its medical robotics and oral insulin platforms.

Management Comments

• Nadav Kidron, CEO of Oramed: 'We believe this transaction represents an important strategic milestone for Oramed. By transferring our POD technology to Lifeward with a significant ownership stake, Oramed shareholders retain substantial exposure to the oral delivery platform while simultaneously gaining meaningful participation in a proven revenue-generating medical robotics business and revenue streams, alongside Oramed's other strategic assets. With Mark Grant's extensive diabetes industry experience at the helm, we are confident in Lifeward's ability to advance both the medical robotics and oral insulin platforms.'
• Mark Grant, President and CEO of Lifeward: 'Oramed is an ideal strategic partner for Lifeward at this pivotal moment in our company's evolution. This transaction is expected to provide us with the financial resources to achieve profitability with our proven ReWalk and AlterG product lines while simultaneously opening significant growth opportunities through the acquisition of Oramed's POD technology. We see significant potential to advance the oral insulin program and build a truly diversified biomedical innovation company.'

Industry Context

This transaction represents a convergence of two distinct but potentially synergistic areas within the biomedical industry: oral drug delivery and medical robotics. Oramed's move to divest its POD technology into a separate, publicly traded entity (Lifeward) while retaining a significant ownership stake allows it to focus on its core while still benefiting from the potential upside of the platform. For Lifeward, a company known for mobility solutions, acquiring a drug delivery platform could diversify its product portfolio and tap into the large diabetes market, especially with the focus on oral insulin. The involvement of an experienced leader like Mark Grant from the diabetes sector suggests a strategic intent to aggressively pursue the oral insulin program. This could signal a trend of smaller biotech firms seeking strategic partnerships or divestitures to fund R&D and leverage existing commercial infrastructures.

Comparison to Industry Standards

• The beneficial ownership of up to 49.99% for Oramed in Lifeward is a substantial stake, indicating a strong strategic partnership rather than a simple asset sale, comparable to a significant minority investment or a reverse merger structure.
• The revenue sharing model (4% of Net Revenue from ReWalk products) is a common mechanism in licensing or strategic partnerships, providing Oramed with a recurring income stream from an established product line.
• The milestone-based additional investment of $10 million (with Oramed investing $9 million) is a standard practice in venture financing and strategic alliances, aligning incentives and de-risking further capital deployment for Oramed based on Lifeward's commercial performance (e.g., 150% ReWalk Unit Sales increase or $1.15 share price).

Corporate Governance

Related Party Transactions

• Oramed Pharmaceuticals Inc. (Seller) is transferring its wholly-owned subsidiary, Oratech Pharma, Inc., to Lifeward Ltd.
• Oramed is receiving Lifeward Ordinary Shares, Pre-Funded Warrants, Share Purchase Warrants, and revenue-based payments from Lifeward as consideration for the transaction.
• Oramed is investing $9,000,000 in Lifeward's initial $10,000,000 senior secured convertible notes private placement and is designated as the 'Lead Investor'.
• Oramed has committed to investing an additional $9,000,000 in a milestone-based $10,000,000 senior secured convertible note offering by Lifeward.
• Oramed Ltd. (an affiliate of Oramed Pharmaceuticals Inc.) will enter into a Clinical Trial Management Agreement with Oratech Pharma, Inc. (now a Lifeward subsidiary) to manage the clinical study of the oral insulin capsule product.

Stakeholder Impact

• Shareholders of Oramed: Will gain significant ownership in Lifeward and exposure to both oral drug delivery and medical robotics, along with potential revenue streams, but face dilution from Lifeward's perspective and a lock-up period.
• Shareholders of Lifeward: Will experience significant dilution from the issuance of shares and warrants to Oramed, but gain Oramed's POD technology and a substantial capital injection to fund operations and growth.
• Employees of Oratech Pharma, Inc.: The company is being acquired by Lifeward, but Oramed will continue to manage the clinical study, suggesting continuity for the oral insulin program.
• Customers of Lifeward (ReWalk Personal Exoskeleton): Potential for continued product development and stability due to new funding and strategic focus.
• Creditors of Lifeward: Benefit from a $10 million (potentially $20 million) capital raise through senior secured convertible notes, improving Lifeward's financial position.

Next Steps

• Lifeward to seek shareholder approval for the issuance of shares exceeding 19.99% of its outstanding ordinary shares.
• Lifeward to file a resale registration statement (Form S-3 or S-1) with the SEC within 75 calendar days after closing to register Oramed's shares and warrants for resale.
• Lifeward to use commercially reasonable efforts to have the resale registration statement declared effective within 45 days (or 75 days for full SEC review) following the Initial Closing.
• Oramed to manage the clinical study of Oratech's oral insulin capsule product under the Clinical Trial Management Agreement.
• Lifeward to hold shareholder meetings at least every four months until shareholder approval for the share issuance is obtained, if not secured at the first meeting.
• Oramed's lock-up period for Lifeward shares will expire 120 days after the closing date.

Key Dates

Recommendation

The filing details a complex strategic transaction that significantly alters Oramed's business model and Lifeward's future prospects. While Oramed gains a substantial stake in a diversified medical technology company and Lifeward secures critical funding and new technology, the immediate impact on share price is uncertain due to the complexities of the deal, including shareholder approvals, milestone-based investments, and potential dilution. Investors should hold to observe the successful completion of the transaction, the integration of the POD technology, and Lifeward's performance against the defined milestones before making further investment decisions.

Keywords

Oramed Pharmaceuticals, Lifeward Ltd, POD technology, oral drug delivery, medical robotics, strategic transaction, convertible notes, warrants, shareholder investment, ReWalk Exoskeleton, Oratech Pharma, clinical trial management, SEC filing, corporate development